Deoxyglucose
In clinical developmentAlso known as 2-DEOXYGLUCOSE, 2-DG, 2-Deoxy-D-Glucose, 2-Deoxy-D-arabino-hexose+2 more
2-DEOXYGLUCOSE, 2-DG, 2-Deoxy-D-Glucose, 2-Deoxy-D-arabino-hexose, 2DG, D-arabino-2-desoxyhexose.
Recent clinical, regulatory, research and industry developments relating to this drug.
4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to exert anti-inflammatory effects.
Obesity induces a phenotypic switch in adipose tissue macrophage polarization.
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Annals of neurology1
- Nature communications1
- The Journal of clinical investigation1
- Berent S1
- Bodzin JL1
- Foster NL1
- Frey KA1
- Fu XW1
- Giordani B1
- Han C1
- Kong LY1
- Center for Molecular Metabolism1
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines1
- Life Sciences Institute1
- University of Michigan Medical School1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 2 of the same disease areas as Deoxyglucose in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials